BAXQT60Baxter International Inc.·NYSE
23.00-2.13%
News
Down 2.1% — What Baxter International (BAX) Said on Its Q3 Earnings Call (marketbeat.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E—EPS (ttm)-1.38Insider Own0.77%Shs Outstand517.00MPerf Week-9.09%
Market Cap11.89BForward P/E11.28EPS next Y2.04Insider Trans0.00%Shs Float513.69MPerf Month-2.71%
Enterprise Value18.72BPEG—EPS next Q—Short Float4.63%Perf Quarter-18.15%
Income-723.00MP/S1.02EPS this Y-12.11%Short Ratio3.63Perf Half Y33.64%
Sales11.61BP/B1.84EPS next Y-1.92%ROA-3.72%Short Interest23.77MPerf YTD20.36%
Book/sh12.52P/C6.02EPS next 5Y1.84%ROE-11.62%52W High30.00 -23.33%Perf Year2.59%
Cash/sh3.82P/FCF11.89EPS past 3/5Y—ROIC-1.34%52W Low15.73 46.22%Perf 3Y-28.48%
Dividend Est.0.04 (0.17%)EV/EBITDA23.35Sales past 3/5Y3.79% -0.75%Gross Margin30.09%Volatility4.75% 3.37%Perf 5Y-72.02%
Dividend TTM0.04 (0.17%)EV/Sales1.61EPS Y/Y TTM—Oper. Margin-1.90%ATR (14)0.91Perf 10Y-52.27%
Dividend Ex-DateNov 27, 2026Quick Ratio1.19Sales Y/Y TTM5.33%Profit Margin-6.23%RSI (14)37.75Recom2.61
Dividend Gr. 3/5Y-23.25% -11.45%Current Ratio1.79EPS Q/Q-15.94%SMA20-6.81%Beta0.66Target Price23.83
Payout—Debt/Eq1.36Sales Q/Q4.97%SMA50-6.43%Rel Volume1.80Prev Close23.50
Employees37,500LT Debt/Eq1.23EarningsFeb 11SMA2007.79%Avg Volume6.53MPrice23.00
IPO DateOct 27, 1981Option/ShortYes / YesEPS/Sales Surpr.11.92% 2.34%Net Debt/EBITDA8.52Volume11,778,189Change-2.13%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-29-26ReiteratedJefferiesHold$19 → $25
Oct-06-26InitiatedBarclaysUnderweight$27 → $20
Jul-31-26ReiteratedStifel NicolausHold$24 → $28
Jul-31-26UpgradeCitigroupSell → Neutral
Jul-28-26ReiteratedStifel NicolausHold$19 → $24
Jul-28-26ReiteratedUBSNeutral$19 → $25
Jul-15-26ReiteratedGoldman SachsNeutral$17 → $21
Jul-06-26ReiteratedEvercore ISI GroupOutperform$23 → $24
May-28-26DowngradeCitigroupNeutral → Sell
May-04-26ReiteratedBarclaysOverweight$25 → $27
Latest News· Times ET
Oct-30-26
Oct-29-26
Oct-26-26
Oct-22-26
Oct-16-26
Oct-15-26
Oct-13-26
Oct-11-26
Oct-09-26
Company

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue11,61111,24410,63610,360—————
Cost of Goods Sold Incl. D&A8,1177,8656,6526,210—————
Gross Profit3,4943,3793,9844,150—————
Selling, General and Administrative Excl. Other2,9542,8902,9672,953—————
Research and Development519518590518—————
Other Operating Expense242279413-28—————
Operating Income-221-30814707—————
Interest Expense285290408508—————
Unusual Expense
—————————
Non-Operating Income (Expense)3199310543—————
Net Income Before Taxes-187-505-289242—————
Income Taxes4323953761—————
Consolidated Net Income-723-957-6492,656—————
Net Income From Continuing Operations-619-900-326181—————
Net Income-723-957-6492,656—————
EPS (Recurring)-1.38-1.75-1.275.25—————
EPS (Basic, Before Extraordinaries)-1.38-1.75-1.275.25—————
EPS (Diluted)-1.38-1.75-1.275.23—————
EBITDA8027661,1161,734—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio———7.39—————
Price To Sales Ratio1.020.871.401.89—————
Gross Margin30.0930.0537.4640.06—————
Operating Margin-1.90-2.740.136.82—————
Net Margin-6.23-8.51-6.1025.64—————
Shares Outstanding517513510506—————
Market Capitalization11,8919,80314,87219,562—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$30.23$26.15$22.08$18.00$13.92● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Mason Jeanne KEVP, Chief HR OfficerMar 01 '24Option Exercise37.1764,4882,397,019206,778Mar 05
Mason Jeanne KEVP, Chief HR OfficerMar 01 '24Sale40.6164,4882,618,858142,290Mar 05
STROUCKEN ALBERT P LDirectorMar 20 '23Option Exercise36.933,930145,13540,765Mar 22
STROUCKEN ALBERT P LDirectorMar 20 '23Sale37.523,930147,45436,835Mar 22
Kunzler JacquelineSVP, Chief Quality OfficerFeb 21 '23Option Exercise37.824,163157,44520,538Feb 23
Kunzler JacquelineSVP, Chief Quality OfficerFeb 21 '23Sale40.503,813154,42716,725Feb 23
Mason Jeanne KSVP, Human ResourcesJan 17 '23Option Exercise18.91118,9542,249,420185,708Jan 19
Mason Jeanne KSVP, Human ResourcesJan 17 '23Sale44.7059,4772,658,622126,231Jan 19
STROUCKEN ALBERT P LDirectorApr 05 '22Option Exercise29.524,020118,67038,147Apr 07
STROUCKEN ALBERT P LDirectorApr 05 '22Sale76.024,020305,61234,127Apr 07
HELLMAN PETER SDirectorApr 05 '22Option Exercise29.524,020118,67031,649Apr 07
HELLMAN PETER SDirectorApr 05 '22Sale76.024,020305,59427,629Apr 07
FORSYTH JOHN DDirectorApr 01 '22Sale77.681,00578,06827,029Apr 05
FORSYTH JOHN DDirectorApr 01 '22Option Exercise0.001,00501,005Apr 05
FORSYTH JOHN DDirectorMar 01 '22Sale84.821,00585,24427,029Mar 03
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.